Benzimidazole compounds or their salts, canine heartworm disease control agents containing said compounds, and methods of using the same
A benzimidazole compound with a furyl group addresses the limitations of existing heartworm treatments by effectively inhibiting dog heartworm larvae, providing a novel and potentially resistance-resistant control method.
Patent Information
- Application Number
- JP2023525919
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-02-15
- Filing Date
- 2022-06-02
- Publication Date
- 2024-12-05
- Estimated Expiration
- 2042-06-02
AI Technical Summary
Current heartworm disease control agents for dogs, such as melarsomine dihydrochloride and macrolide preventive drugs, face issues with long-term use leading to drug resistance and require year-round administration, necessitating the development of new compounds with improved efficacy against heartworms.
A benzimidazole compound with a furyl group at the 2-position, represented by general formulas (1) and (1A), or its salts, exhibits excellent insecticidal effects against dog heartworms, providing a novel approach to control and prevent heartworm infections.
The benzimidazole compound effectively inhibits the motility and growth of heartworm larvae, offering a promising alternative to existing drugs by potentially reducing resistance and simplifying treatment protocols.
Smart Images

Figure 0007595161000001 
Figure 0007595161000002 
Figure 0007595161000003
Abstract
Description
[Technical field]
[0001] The present invention relates to an agent for controlling heartworm disease in animals, which contains a benzimidazole compound or a salt thereof as an active ingredient, and a method for using the same. [Background technology]
[0002] Heartworm infection is caused by the mosquito-borne Dirofilaria immitis and occurs in many animal species and pets. The mechanism is that when a mosquito ingests microfilariae (new larval stage), they molt repeatedly inside the body and grow into infective larvae (L3). The infective larvae reach the host's skin when the mosquito feeds on the animal, and the larvae begin to invade and grow inside the animal. The infective larvae molt within 3 to 12 days and enter the fourth stage (L4), and after remaining in the subcutaneous tissue, abdomen, and chest for about 2 months, the L4 larvae undergo a final molt to become young adults and reach the host's heart and pulmonary arteries about 70 to 120 days after initial infection.
[0003] On the other hand, it has been reported that benzimidazole compounds having a pyridyl group at the 2-position are effective in controlling external or internal parasites in animals (see, for example, Patent Document 1), but this document does not disclose any description of benzimidazole compounds having a furyl group at the 2-position or the insecticidal effect of said compounds against dog heartworms. [Prior art documents] [Patent documents]
[0004] [Patent Document 1] International Publication No. 2019 / 225663 Brochure Summary of the Invention [Problem to be solved by the invention]
[0005] Melarsomine dihydrochloride is known as a canine heartworm control agent, and it is effective against both mature (adult) and immature heartworms. Heartworm infection can be prevented by macrolide prophylactic drugs, but year-round prevention is recommended regardless of the animal's living conditions. There is concern that long-term use of these drugs in animals may lead to the development of resistance to existing drugs, and there is a need for new drugs that are active against heartworms and can be used to treat infection caused by them. [Means for solving the problem]
[0006] As a result of intensive research aimed at solving the above-mentioned problems, the present inventors have found that a benzimidazole compound having a furyl group at the 2-position, represented by general formula (1) or (1A), or a salt thereof, not only has an excellent effect of controlling canine heartworm disease, but also can solve the above-mentioned problems, thereby arriving at the present invention. That is, the present invention is [1] General formula (1) [ka] {In the formula, R is (a1) a hydrogen atom; (a2) a (C1-C6) alkyl group; (a3) a halo(C1-C6) alkyl group; (a4) a (C2-C6) alkenyl group; (a5) a (C2-C6) alkynyl group; (a6) a (C1-C6) alkoxy(C1-C6) alkyl group; (a7) a (C1-C6) alkylthio(C1-C6) alkyl group; (a8) a (C1-C6) alkoxycarbonyl(C1-C6) alkyl group; (a9) a (C1-C6) alkoxycarbonyl group; (a10) an aryl group; or (a11). an aryl group having 1 to 5 substituents which may be the same or different and are selected from (a) a halogen atom, (b) a (C1-C6) alkyl group, (c) a halo(C1-C6) alkyl group, (d) a (C1-C6) alkoxy group, (e) a halo(C1-C6) alkoxy group, (f) a (C1-C6) alkylthio group, (g) a halo(C1-C6) alkylthio group, (h) a (C1-C6) alkylsulfinyl group, (i) a halo(C1-C6) alkylsulfinyl group, (l) a nitro group, and (m) a trimethylsilyl group; (a12) an aryl(C1-C6) alkyl group; and (a13) an aryl(C1-C6)alkyl group having 1 to 5 substituents which may be the same or different and are selected from (a) a halogen atom, (b) a (C1-C6)alkyl group, (c) a halo(C1-C6)alkyl group, (d) a (C1-C6)alkoxy group, (e) a halo(C1-C6)alkoxy group, (f) a (C1-C6)alkylthio group, (g) a halo(C1-C6)alkylthio group, (h) a (C1-C6)alkylsulfinyl group, (i) a halo(C1-C6)alkylsulfinyl group, (j) a (C1-C6)alkylsulfonyl group, (k) a halo(C1-C6)alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group; (a14) an aryl(C2-C6)alkenyl group;(a15) an aryl(C2-C6)alkenyl group having 1 to 5 substituents which may be the same or different and are selected from (a) a halogen atom, (b) a (C1-C6)alkyl group, (c) a halo(C1-C6)alkyl group, (d) a (C1-C6)alkoxy group, (e) a halo(C1-C6)alkoxy group, (f) a (C1-C6)alkylthio group, (g) a halo(C1-C6)alkylthio group, (h) a (C1-C6)alkylsulfinyl group, (i) a halo(C1-C6)alkylsulfinyl group, (j) a (C1-C6)alkylsulfonyl group, (k) a halo(C1-C6)alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group; (a16) an aryl(C1-C6)alkoxy(C1-C6)alkyl group; (a17) aryl(C1-C6)alkoxy(C1-C6)alkyl groups having 1 to 5 substituents which may be the same or different and are selected from (a) halogen atoms, (b) (C1-C6)alkyl groups, (c) halo(C1-C6)alkyl groups, (d) (C1-C6)alkoxy groups, (e) halo(C1-C6)alkoxy groups, (f) (C1-C6)alkylthio groups, (g) halo(C1-C6)alkylthio groups, (h) (C1-C6)alkylsulfinyl groups, (i) halo(C1-C6)alkylsulfinyl groups, (j) (C1-C6)alkylsulfonyl groups, (k) halo(C1-C6)alkylsulfonyl groups, (l) nitro groups, and (m) trimethylsilyl groups; (a18) R; 3 R 4 N group (where R 3 and R 4 may be the same or different, and each represents (aa) a hydrogen atom, (ab) a (C1-C6) alkyl group, (ac) a (C1-C6) alkoxy group, (ad) a (C1-C6) alkoxycarbonyl group, (ae) a (C1-C6) alkylsulfonyl group, (af) a halo(C1-C6) alkylsulfonyl group, or (ag) a phenyl group. ); (a19) R 3 R 4 N carbonyl group (where R 3 and R 4 is the same as above. );(a20) R 3 R 4 N-thiocarbonyl group (where R 3 and R 4is the same as above; or (a21) R 3 R 4 N sulfonyl group (where R 3 and R 4 is the same as above. ); Y 1 and Y 4 may be the same or different and represent (d1) a hydrogen atom; (d2) a halogen atom; or (d3) a (C1-C6) alkyl group. Y 2 and Y 3 may be the same or different, (e1) a hydrogen atom; (e2) a halogen atom; (e3) a (C1-C6) alkyl group; (e4) a (C1-C6) alkoxy group; (e5) a halo(C1-C6) alkyl group; (e6) a halo(C1-C6) alkoxy group; (e7) an aryloxy group; (e8) an aryloxy group having 1 to 5 substituents which may be the same or different and are selected from (a) a halogen atom, (b) a (C1-C6) alkyl group, (c) a halo(C1-C6) alkyl group, (d) a (C1-C6) alkoxy group, (e) a halo(C1-C6) alkoxy group, (f) a (C1-C6) alkylthio group, (g) a halo(C1-C6) alkylthio group, (h) a (C1-C6) alkylsulfinyl group, (i) a halo(C1-C6) alkylsulfinyl group, (j) a (C1-C6) alkylsulfonyl group, (k) a halo(C1-C6) alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group; (e9) an arylcarbonyl group; or (e10) and (c) an aryloxy group having 1 to 5 substituents selected from the group consisting of (a) a halogen atom, (b) a (C1-C6) alkyl group, (c) a halo(C1-C6) alkyl group, (d) a (C1-C6) alkoxy group, (e) a halo(C1-C6) alkoxy group, (f) a (C1-C6) alkylthio group, (g) a halo(C1-C6) alkylthio group, (h) a (C1-C6) alkylsulfinyl group, (i) a halo(C1-C6) alkylsulfinyl group, (j) a (C1-C6) alkylsulfonyl group, (k) a halo(C1-C6) alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group. X may be the same or different, (c1) a hydrogen atom; (c2) a halogen atom; (b1) (C6-C 12 ) alkyl group; (b2) (C6-C 12 ) an alkenyl group; or (b3) (C6-C 12 ) an alkynyl group; n is an integer equal to 3.} A veterinary heartworm control agent comprising, as an active ingredient, a benzimidazole compound represented by the following formula (I): [2] A method for using the canine heartworm disease control agent for animals, which comprises administering an effective amount of the canine heartworm disease control agent for animals according to [1] to an animal. [3] General formula (1A) [ka] {In the formula, R is (a1) a hydrogen atom; (a2) a (C1-C6) alkyl group; (a3) a halo(C1-C6) alkyl group; (a4) a (C2-C6) alkenyl group; (a5) a (C2-C6) alkynyl group; (a6) a (C1-C6) alkoxy(C1-C6) alkyl group; (a7) a (C1-C6) alkylthio(C1-C6) alkyl group; (a8) a (C1-C6) alkoxycarbonyl(C1-C6) alkyl group; (a9) a (C1-C6) alkoxycarbonyl group; (a10) an aryl group; or (a11). an aryl group having 1 to 5 substituents which may be the same or different and are selected from (a) a halogen atom, (b) a (C1-C6) alkyl group, (c) a halo(C1-C6) alkyl group, (d) a (C1-C6) alkoxy group, (e) a halo(C1-C6) alkoxy group, (f) a (C1-C6) alkylthio group, (g) a halo(C1-C6) alkylthio group, (h) a (C1-C6) alkylsulfinyl group, (i) a halo(C1-C6) alkylsulfinyl group, (l) a nitro group, and (m) a trimethylsilyl group; (a12) an aryl(C1-C6) alkyl group; and (a13) an aryl(C1-C6)alkyl group having 1 to 5 substituents which may be the same or different and are selected from (a) a halogen atom, (b) a (C1-C6)alkyl group, (c) a halo(C1-C6)alkyl group, (d) a (C1-C6)alkoxy group, (e) a halo(C1-C6)alkoxy group, (f) a (C1-C6)alkylthio group, (g) a halo(C1-C6)alkylthio group, (h) a (C1-C6)alkylsulfinyl group, (i) a halo(C1-C6)alkylsulfinyl group, (j) a (C1-C6)alkylsulfonyl group, (k) a halo(C1-C6)alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group; (a14) an aryl(C2-C6)alkenyl group;(a15) an aryl(C2-C6)alkenyl group having 1 to 5 substituents which may be the same or different and are selected from (a) a halogen atom, (b) a (C1-C6)alkyl group, (c) a halo(C1-C6)alkyl group, (d) a (C1-C6)alkoxy group, (e) a halo(C1-C6)alkoxy group, (f) a (C1-C6)alkylthio group, (g) a halo(C1-C6)alkylthio group, (h) a (C1-C6)alkylsulfinyl group, (i) a halo(C1-C6)alkylsulfinyl group, (j) a (C1-C6)alkylsulfonyl group, (k) a halo(C1-C6)alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group; (a16) an aryl(C1-C6)alkoxy(C1-C6)alkyl group; (a17) aryl(C1-C6)alkoxy(C1-C6)alkyl groups having 1 to 5 substituents which may be the same or different and are selected from (a) halogen atoms, (b) (C1-C6)alkyl groups, (c) halo(C1-C6)alkyl groups, (d) (C1-C6)alkoxy groups, (e) halo(C1-C6)alkoxy groups, (f) (C1-C6)alkylthio groups, (g) halo(C1-C6)alkylthio groups, (h) (C1-C6)alkylsulfinyl groups, (i) halo(C1-C6)alkylsulfinyl groups, (j) (C1-C6)alkylsulfonyl groups, (k) halo(C1-C6)alkylsulfonyl groups, (l) nitro groups, and (m) trimethylsilyl groups; (a18) R; 3 R 4 N group (where R 3 and R 4 may be the same or different, and each represents (aa) a hydrogen atom, (ab) a (C1-C6) alkyl group, (ac) a (C1-C6) alkoxy group, (ad) a (C1-C6) alkoxycarbonyl group, (ae) a (C1-C6) alkylsulfonyl group, (af) a halo(C1-C6) alkylsulfonyl group, or (ag) a phenyl group. ); (a19) R 3 R 4 N carbonyl group (where R 3 and R 4 is the same as above. );(a20) R 3 R 4 N-thiocarbonyl group (where R 3 and R 4is the same as above; or (a21) R 3 R 4 N sulfonyl group (where R 3 and R 4 is the same as above. ); X 1 (b1) (C6‐C 12 ) alkyl group; (b2) (C6-C 12 ) an alkenyl group; or (b3) (C6-C 12 ) an alkynyl group; X 2 and X 3 may be the same or different and represent (c1) a hydrogen atom; (c2) a halogen atom; or (c3) a (C1-C6) alkyl group. Y 1 and Y 4 may be the same or different and represent (d1) a hydrogen atom; (d2) a halogen atom; or (d3) a (C1-C6) alkyl group. Y 2 and Y 3may be the same or different, (e1) a hydrogen atom; (e2) a halogen atom; (e3) a (C1-C6) alkyl group; (e4) a (C1-C6) alkoxy group; (e5) a halo(C1-C6) alkyl group; (e6) a halo(C1-C6) alkoxy group; (e7) an aryloxy group; (e8) an aryloxy group having 1 to 5 substituents which may be the same or different and are selected from (a) a halogen atom, (b) a (C1-C6) alkyl group, (c) a halo(C1-C6) alkyl group, (d) a (C1-C6) alkoxy group, (e) a halo(C1-C6) alkoxy group, (f) a (C1-C6) alkylthio group, (g) a halo(C1-C6) alkylthio group, (h) a (C1-C6) alkylsulfinyl group, (i) a halo(C1-C6) alkylsulfinyl group, (j) a (C1-C6) alkylsulfonyl group, (k) a halo(C1-C6) alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group; (e9) an arylcarbonyl group; or (e10) An aryloxy group having 1 to 5 substituents, which may be the same or different, selected from (a) a halogen atom, (b) a (C1-C6) alkyl group, (c) a halo (C1-C6) alkyl group, (d) a (C1-C6) alkoxy group, (e) a halo (C1-C6) alkoxy group, (f) a (C1-C6) alkylthio group, (g) a halo (C1-C6) alkylthio group, (h) a (C1-C6) alkylsulfinyl group, (i) a halo (C1-C6) alkylsulfinyl group, (j) a (C1-C6) alkylsulfonyl group, (k) a halo (C1-C6) alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group.} or a salt thereof, [4] R is: (a1) a hydrogen atom; (a2) a (C1-C6) alkyl group; (a3) a halo(C1-C6) alkyl group; (a4) a (C2-C6) alkenyl group; (a5) a (C2-C6) alkynyl group; (a6) a (C1-C6) alkoxy(C1-C6) alkyl group; (a7) a (C1-C6) alkylthio(C1-C6) alkyl group; (a8) a (C1-C6) alkoxycarbonyl(C1-C6) alkyl group; (a9) a (C1-C6) alkoxycarbonyl group; (a11). an aryl group having 1 to 5 substituents which may be the same or different and are selected from (a) a halogen atom, (b) a (C1-C6) alkyl group, (c) a halo(C1-C6) alkyl group, (d) a (C1-C6) alkoxy group, (e) a halo(C1-C6) alkoxy group, (f) a (C1-C6) alkylthio group, (g) a halo(C1-C6) alkylthio group, (h) a (C1-C6) alkylsulfinyl group, (i) a halo(C1-C6) alkylsulfinyl group, (l) a nitro group, and (m) a trimethylsilyl group; (a12) an aryl(C1-C6) alkyl group; and (a13) an aryl(C1-C6)alkyl group having 1 to 5 substituents which may be the same or different and are selected from (a) a halogen atom, (b) a (C1-C6)alkyl group, (c) a halo(C1-C6)alkyl group, (d) a (C1-C6)alkoxy group, (e) a halo(C1-C6)alkoxy group, (f) a (C1-C6)alkylthio group, (g) a halo(C1-C6)alkylthio group, (h) a (C1-C6)alkylsulfinyl group, (i) a halo(C1-C6)alkylsulfinyl group, (j) a (C1-C6)alkylsulfonyl group, (k) a halo(C1-C6)alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group; (a14) an aryl(C2-C6)alkenyl group; (a16) an aryl(C1-C6)alkoxy(C1-C6)alkyl group; (a20) R 3 R 4 N-thiocarbonyl group (where R 3 and R 4 is the same as above; or (a21) R 3 R 4 N sulfonyl group (where R 3 and R 4 is the same as above. ); X1 But (b1) (C6-C 12 ) an alkyl group; or (b3) (C6-C 12 ) an alkynyl group; X 2 and X 3 may be the same or different, and represent (c1) a hydrogen atom; or (c2) a halogen atom; Y 1 and Y 4 may be the same or different, and represent (d1) a hydrogen atom; (d2) a halogen atom; or (d3) a (C1-C6) alkyl group; Y 2 and Y 3 may be the same or different and represent (e1) a hydrogen atom; (e2) a halogen atom; (e3) a (C1-C6) alkyl group; (e4) a (C1-C6) alkoxy group; (e5) a halo(C1-C6) alkyl group; (e6) a halo(C1-C6) alkoxy group; (e7) an aryloxy group; or (e9) an arylcarbonyl group. [3] A benzimidazole compound or a salt thereof according to the present invention. [5] A control agent for heartworm disease for animals, comprising the benzimidazole compound or its salt according to any one of [3] to [4] as an active ingredient. [6] A method for using an agent for controlling heartworm disease in animals, comprising administering to an animal an effective amount of the benzimidazole compound or a salt thereof according to any one of [3] to [4]. Regarding. Effect of the Invention
[0007] The benzimidazole compound having a furyl group at the 2-position of the present invention or a salt thereof has an excellent effect as an agent for controlling canine heartworm disease. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0008] In the definition of the general formulas (1) and (1A) of the benzimidazole compound having a furyl group at the 2-position or a salt thereof of the present invention, "halo" means a "halogen atom" and represents a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom.
[0009] The term "(C1-C6) alkyl group" refers to a linear or branched alkyl group having 1 to 6 carbon atoms, such as a methyl group, an ethyl group, a normal propyl group, an isopropyl group, a normal butyl group, an isobutyl group, a secondary butyl group, a tertiary butyl group, a normal pentyl group, an isopentyl group, a tertiary pentyl group, a neopentyl group, a 2,3-dimethylpropyl group, a 1-ethylpropyl group, a 1-methylbutyl group, a 2-methylbutyl group, a normal hexyl group, an isohexyl group, a 2-hexyl group, a 3-hexyl group, a 2-methylpentyl group, a 3-methylpentyl group, a 1,1,2-trimethylpropyl group, or a 3,3-dimethylbutyl group; The term "(C2-C6) alkenyl group" refers to a linear or branched alkenyl group having 2 to 6 carbon atoms, such as a vinyl group, an allyl group, an isopropenyl group, a 1-butenyl group, a 2-butenyl group, a 2-methyl-2-propenyl group, a 1-methyl-2-propenyl group, a 2-methyl-1-propenyl group, a pentenyl group, a 1-hexenyl group, or a 3,3-dimethyl-1-butenyl group; The term "(C2-C6)alkynyl group" refers to a straight-chain or branched alkynyl group having 2 to 6 carbon atoms, such as an ethynyl group, a 1-propynyl group, a 2-propynyl group, a 1-butynyl group, a 2-butynyl group, a 3-butynyl group, a 3-methyl-1-propynyl group, a 2-methyl-3-propynyl group, a pentynyl group, a 1-hexynyl group, a 3-methyl-1-butynyl group, or a 3,3-dimethyl-1-butynyl group.
[0010] "(C6-C 12The term "alkyl group" refers to a linear or branched alkyl group having 6 to 12 carbon atoms, such as a normal hexyl group, an isohexyl group, a 2-hexyl group, a 3-hexyl group, a 2-methylpentyl group, a 3-methylpentyl group, a 1,1,2-trimethylpropyl group, a 3,3-dimethylbutyl group, a heptyl group, an octyl group, a nonyl group, a decyl group, an undecyl group, or a dodecyl group, "(C6-C 12 The term "alkenyl group" refers to a linear or branched alkenyl group having 6 to 12 carbon atoms, such as a 1,3-dimethyl-1-pentenyl group, a 1,3-dimethyl-2-pentenyl group, a 1,3-dimethyl-3-pentenyl group, a 1-hexenyl group, a 2-hexenyl group, a 3-hexenyl group, a 4-hexenyl group, a 5-hexenyl group, a 1-octenyl group, a 1-nonenyl group, a 1-decenyl group, a 1-undecenyl group, or a 1-dodecenyl group, "(C6-C 12 The term "alkynyl group" refers to a straight-chain or branched-chain alkynyl group having 6 to 12 carbon atoms, such as a 1-hexynyl group, 1,1-dimethyl-2-butynyl group, 1-pentynyl group, 1-hexynyl group, 1-heptynyl group, 1-octynyl group, 1-nonynyl group, 1-decynyl group, 1-undecynyl group, 1-dodecynyl group, and the like.
[0011] The term "(C1-C6)alkoxy group" refers to a straight-chain or branched-chain alkoxy group having 1 to 6 carbon atoms, such as a methoxy group, ethoxy group, normal propoxy group, isopropoxy group, normal butoxy group, sec. butoxy group, tertiary butoxy group, normal pentyloxy group, isopentyloxy group, tertiary pentyloxy group, neopentyloxy group, 2,3-dimethylpropyloxy group, 1-ethylpropyloxy group, 1-methylbutyloxy group, normal hexyloxy group, isohexyloxy group, or 1,1,2-trimethylpropyloxy group.
[0012] Examples of the "(C1-C6) alkylthio group" include a methylthio group, an ethylthio group, a normal propylthio group, an isopropylthio group, a normal butylthio group, a secondary butylthio group, a tertiary butylthio group, a normal pentylthio group, an isopentylthio group, a tertiary pentylthio group, a neopentylthio group, a 2,3-dimethylpropylthio group, a 1-ethylpropylthio group, a 1-methylbutylthio group, a normal hexylthio group, an isohexylthio group, and a 1,1,2-trimethylpropylthio group. and examples of the "(C1-C6) alkylsulfinyl group" include a methylsulfinyl group, an ethylsulfinyl group, a normal propylsulfinyl group, an isopropylsulfinyl group, a normal butylsulfinyl group, a secondary butylsulfinyl group, a tertiary butylsulfinyl group, a normal pentylsulfinyl group, an isopentylsulfinyl group, a tertiary pentylsulfinyl group, a neopentylsulfinyl group, a 2,3 and the like. Examples of the "(C1-C6)alkylsulfonyl group" include a linear or branched alkylsulfonyl group having 1 to 6 carbon atoms, such as a methylsulfonyl group, an ethylsulfonyl group, a linear propylsulfonyl group, an isopropylsulfonyl group, a linear butylsulfonyl group, a secondary butylsulfonyl group, a tertiary butylsulfonyl group, a linear pentylsulfonyl group, an isopentylsulfonyl group, a tertiary pentylsulfonyl group, a neopentylsulfonyl group, a 2,3-dimethylpropylsulfonyl group, a 1-ethylpropylsulfonyl group, a 1-methylbutylsulfonyl group, a linear hexylsulfonyl group, an isohexylsulfonyl group, and a 1,1,2-trimethylpropylsulfonyl group.
[0013] The "(C1-C6)alkoxycarbonyl group" refers to an alkoxycarbonyl group composed of a straight-chain or branched-chain alkoxy group having 1 to 6 carbon atoms and a carbonyl group, such as a methoxycarbonyl group, ethoxycarbonyl group, normal propoxycarbonyl group, isopropoxycarbonyl group, normal butoxycarbonyl group, secondary butoxycarbonyl group, tertiary butoxycarbonyl group, normal pentyloxycarbonyl group, isopentyloxycarbonyl group, tertiary pentyloxycarbonyl group, neopentyloxycarbonyl group, 2,3-dimethylpropyloxycarbonyl group, 1-ethylpropyloxycarbonyl group, 1-methylbutyloxycarbonyl group, normal hexyloxycarbonyl group, isohexyloxycarbonyl group, or 1,1,2-trimethylpropyloxycarbonyl group.
[0014] The term "aryl group" refers to an aromatic hydrocarbon group having 6 to 10 carbon atoms, such as a phenyl group, a 1-naphthyl group, or a 2-naphthyl group.
[0015] One or more halogen atoms may be substituted at any possible position of the "(C1-C6) alkyl group", "(C2-C6) alkenyl group", "(C2-C6) alkynyl group", "(C1-C6) alkoxy group", "(C1-C6) alkylthio group", "(C1-C6) alkylsulfinyl group", or "(C1-C6) alkylsulfonyl group", and when there are two or more halogen atoms substituted, the halogen atoms may be the same or different. They are respectively represented as "halo(C1-C6) alkyl group", "halo(C2-C6) alkenyl group", "halo(C2-C6) alkynyl group", "halo(C3-C6) cycloalkyl group", "halo(C1-C6) alkoxy group", "halo(C1-C6) alkylthio group", "halo(C1-C6) alkylsulfinyl group", or "halo(C1-C6) alkylsulfonyl group".
[0016] Expressions such as "(C1-C6)", "(C2-C6)" indicate the range of carbon atoms of various substituents. Furthermore, the above definitions can be applied to the groups to which the above substituents are linked, for example, "(C1-C6)alkoxy(C1-C6)alkyl" indicates that a linear or branched alkoxy group having 1 to 6 carbon atoms is linked to a linear or branched alkyl group having 1 to 6 carbon atoms.
[0017] Examples of salts of the benzimidazole compounds represented by the general formulae (1) and (1A) of the present invention include inorganic acid salts such as hydrochloride, sulfate, nitrate, and phosphate; organic acid salts such as acetate, fumarate, maleate, oxalate, methanesulfonate, benzenesulfonate, and paratoluenesulfonate; and salts with inorganic or organic bases such as sodium ion, potassium ion, calcium ion, and trimethylammonium.
[0018] The benzimidazole compounds or salts thereof represented by the general formulae (1) and (1A) of the present invention may have one asymmetric center in their structural formulae, and the present invention includes all of the optical isomers and mixtures containing them in any ratio. The benzimidazole compounds or salts thereof represented by the general formulae (1) and (1A) of the present invention may have two geometric isomers derived from a carbon-carbon double bond in their structural formulae, and the present invention includes all of the geometric isomers and mixtures containing them in any ratio. The benzimidazole compounds or salts thereof represented by the general formulae (1) and (1A) of the present invention may have tautomers in their structural formulae, and the present invention includes all of the tautomers and mixtures containing them in any ratio.
[0019] In the benzimidazole compound or its salt represented by the general formula (1) or (1A) which is the active ingredient of the canine heartworm disease control agent of the present invention, R is preferably (a1) a hydrogen atom; (a2) a (C1-C6) alkyl group; (a3) a halo(C1-C6) alkyl group; (a4) a (C2-C6) alkenyl group; (a5) a (C2-C6) alkynyl group; (a6) a (C1-C6) alkoxy(C1-C6) alkyl group; (a7) a (C1-C6) alkylthio(C1-C6) alkyl group; (a8) a (C1-C6) alkoxycarbonyl(C1-C6) alkyl group; (a9) a (C1-C6) alkoxycarbonyl group; (a11). an aryl group having 1 to 5 substituents which may be the same or different and are selected from (a) a halogen atom, (b) a (C1-C6) alkyl group, (c) a halo(C1-C6) alkyl group, (d) a (C1-C6) alkoxy group, (e) a halo(C1-C6) alkoxy group, (f) a (C1-C6) alkylthio group, (g) a halo(C1-C6) alkylthio group, (h) a (C1-C6) alkylsulfinyl group, (i) a halo(C1-C6) alkylsulfinyl group, (l) a nitro group, and (m) a trimethylsilyl group; (a12) an aryl(C1-C6) alkyl group; and (a13) an aryl(C1-C6)alkyl group having 1 to 5 substituents which may be the same or different and are selected from (a) a halogen atom, (b) a (C1-C6)alkyl group, (c) a halo(C1-C6)alkyl group, (d) a (C1-C6)alkoxy group, (e) a halo(C1-C6)alkoxy group, (f) a (C1-C6)alkylthio group, (g) a halo(C1-C6)alkylthio group, (h) a (C1-C6)alkylsulfinyl group, (i) a halo(C1-C6)alkylsulfinyl group, (j) a (C1-C6)alkylsulfonyl group, (k) a halo(C1-C6)alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group; (a14) an aryl(C2-C6)alkenyl group; (a16) an aryl(C1-C6)alkoxy(C1-C6)alkyl group; (a20) R 3 R 4 N-thiocarbonyl group (where R 3 and R 4 is the same as above; or (a21) R 3 R 4 N sulfonyl group (where R 3 and R 4 is the same as above; ); and More preferably, it is (a1) a hydrogen atom; (a2) a (C1-C6) alkyl group; or (a16) an aryl(C1-C6) alkoxy(C1-C6) alkyl group.
[0020] In the benzimidazole compound represented by the general formula (1) or a salt thereof, X may be the same or different, and is preferably (c1) a hydrogen atom; (c2) a halogen atom; (b1) (C6-C 12 ) an alkyl group; or (b3) (C6-C 12 ) an alkynyl group; More preferably, (b1) (C6-C 12 ) an alkyl group; or (b3) (C6-C 12 ) an alkynyl group;
[0021] In the benzimidazole compound represented by the general formula (1A) or a salt thereof, X 1 As the C6-C 12 ) alkyl group; or (b3) (C6-C 12 ) an alkynyl group; More preferably, (b3) (C6-C 12 ) an alkynyl group;
[0022] In the benzimidazole compound represented by the general formula (1A) or a salt thereof, X 2 and X 3 are preferably, the same or different, (c1) a hydrogen atom; or (c2) a halogen atom; More preferably, it is (c1) a hydrogen atom.
[0023] In the benzimidazole compound or a salt thereof represented by the general formula (1) or (1A), Y 1 and Y 4 are preferably, which may be the same or different, (d1) a hydrogen atom; (d2) a halogen atom; or (d3) a (C1-C6) alkyl group.
[0024] In the benzimidazole compound or a salt thereof represented by the general formula (1) or (1A), Y 2 and Y 3 are preferably, which may be the same or different, (e1) a hydrogen atom; (e2) a halogen atom; (e3) a (C1-C6) alkyl group; (e4) a (C1-C6) alkoxy group; (e5) a halo(C1-C6) alkyl group; (e6) a halo(C1-C6) alkoxy group; (e7) an aryloxy group; or (e9) an arylcarbonyl group.
[0025] The benzimidazole compounds represented by general formulas (1) and (1A) or salts thereof, which are the active ingredients of the canine heartworm disease control agent of the present invention, can be produced, for example, by the following production methods, although the present invention is not limited thereto.
[0026] The nitrogen-containing heterocyclic compound used in the above production method can be a commercially available product as it is, but it can also be produced by the following method and used.
[0027] Manufacturing Method of the Compound of the Present Application 1 [ka]
[0028] Manufacturing method of step [A] The furyl compound represented by the general formula (2-1) can be produced in accordance with a method described in the literature (Tetrahedron Lett. 1975, 50, 4467; Synthesis, 364-365 (1981); Organic Letters, 11(1), 221-224; 2009), which is known as the Sonogashira reaction of a halofuryl compound represented by the general formula (2) with an acetylene compound represented by the general formula (3) using a palladium catalyst and a copper compound.
[0029] Examples of the palladium catalyst that can be used include palladium chloride (II), palladium acetate (II), bistriphenylphosphine dichloropalladium (II), diphenylphosphinoferrocenedichloropalladium (II), tetrakis(triphenylphosphine)palladium (0), dichloroditriphenylphosphinopalladium (0), tris(dibenzylideneacetone)dipalladium (0), etc. The amount of the palladium catalyst used is usually 0.01 to 0.5 mol per mol of the compound represented by the general formula (2).
[0030] Examples of copper compounds that can be used include monovalent copper halides such as copper (I) fluoride, copper (I) chloride, copper (I) bromide, and copper (I) iodide, and divalent copper halides such as copper (II) chloride, copper (II) bromide, and copper (II) iodide, etc. The amount of copper halide used is usually 0.01 to 1 mole per mole of the compound represented by the general formula (2).
[0031] A base is used in this reaction, and examples of the base that can be used include inorganic bases such as sodium hydroxide, potassium hydroxide, calcium hydroxide, barium hydroxide, sodium carbonate, potassium carbonate, potassium hydrogen carbonate, sodium hydrogen carbonate, cesium carbonate, potassium phosphate, etc., and amines such as triethylamine, pyridine, piperidine, etc. The amount of the base used is usually 1 to 10 moles per mole of the compound represented by the general formula (2).
[0032] This reaction can be carried out in a solvent. The organic solvent that can be used is not particularly limited as long as it is inert to the reaction. For example, ether solvents such as dioxane, 1,2-dimethoxyethane, tetrahydrofuran, etc., aromatic hydrocarbon solvents such as toluene, benzene, xylene, etc., aliphatic hydrocarbon solvents such as n-pentane, n-hexane, n-heptane, etc., amide solvents such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, etc., nitrile solvents such as acetonitrile, benzonitrile, etc., and mixed solvents consisting of two or more of these solvents; etc. can be mentioned.
[0033] The reaction temperature is a temperature at which the coupling reaction can be completed, and is usually within the range of room temperature to the boiling point of the solvent used. The reaction time is usually several minutes to several tens of hours. The reaction is preferably carried out under an inert gas atmosphere. After the reaction is completed, the target product may be isolated from the reaction system containing the target product by a conventional method, and the target product can be produced by purifying it by recrystallization, column chromatography, etc. as necessary.
[0034] Manufacturing method of step [B] The benzimidazole compound represented by the general formula (1-2) can be produced by reacting a furyl compound represented by the general formula (2-1) with a nitroaniline compound represented by the general formula (4) in the presence of a reducing agent and an inert solvent.
[0035] The reducing agent used in this reaction can be, for example, hydrosulfites such as sodium dithionite, and the amount used is usually within the range of 2 to 10 times the molar amount of the compound represented by the general formula (4).
[0036] The inert solvent used in this reaction may be any solvent that does not significantly inhibit the progress of this reaction. Examples of the inert solvent include alcohols such as methanol, ethanol, propanol, and isopropanol; aromatic hydrocarbons such as benzene, toluene, and xylene; halogenated aromatic hydrocarbons such as chlorobenzene and dichlorobenzene; chain or cyclic ethers such as diethyl ether, methyl tertiary butyl ether, dioxane, and tetrahydrofuran; amides such as dimethylformamide and dimethylacetamide; ketones such as acetone and methyl ethyl ketone; polar solvents such as dimethyl sulfoxide, 1,3-dimethyl-2-imidazolidinone, and N-methylpyrrolidone; and water. These inert solvents may be used alone or in combination of two or more.
[0037] Since this reaction is an equimolar reaction, each raw material may be used in equimolar amounts, but any of the reactants may be used in excess. The reaction temperature may range from room temperature to the boiling point of the inert solvent used, and the reaction time may vary depending on the reaction scale and reaction temperature, but may be within the range of several minutes to 48 hours.
[0038] After the reaction is completed, the target product may be isolated from the reaction system containing the target product by a conventional method, and the target product can be produced by purifying it, if necessary, by recrystallization, column chromatography, etc. Alternatively, the next step may be carried out without isolating the intermediate from the reaction system.
[0039] Manufacturing method of step [C] The benzimidazole compound represented by general formula (1-1) can be produced by reacting the benzimidazole compound represented by general formula (1-2) with a compound represented by RL (wherein L represents a leaving group such as a halogen atom) in the presence of an inert solvent and a base.
[0040] Examples of the base used in this reaction include inorganic bases such as sodium hydride, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogen carbonate, and potassium hydrogen carbonate; acetates such as sodium acetate and potassium acetate; and the like. The amount of the base used is usually within a range of 1 to 10 times the molar amount of the compound represented by the general formula (1-2).
[0041] The compound represented by RL is usually used in an amount within a range of 1 to 10 times by mol relative to the compound represented by general formula (1-2).
[0042] The inert solvent that can be used in this reaction may be any solvent that does not significantly inhibit this reaction, and examples thereof include aromatic hydrocarbons such as benzene, toluene, xylene, etc.; halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, etc.; halogenated aromatic hydrocarbons such as chlorobenzene, dichlorobenzene, etc.; and chain or cyclic ethers such as diethyl ether, tetrahydrofuran (THF), dioxane, etc. These inert solvents can be used alone or in combination of two or more kinds.
[0043] The reaction temperature in this reaction is usually within the range of about 0°C to the boiling point of the solvent used, and the reaction time varies depending on the reaction scale, reaction temperature, etc., and is not constant, but may be appropriately selected within the range of several minutes to 48 hours.
[0044] After the reaction is completed, the target product may be isolated by a conventional method, and if necessary, purified by recrystallization, distillation, or the like to obtain the target product.
[0045] Next, specific examples of the compound of the present invention are shown below. In the following table, Me represents a methyl group, Et represents an ethyl group, n-Bu represents a normal butyl group, Ph represents a phenyl group, and Bn represents a benzyl group.
[0046] Physical properties are H 1 -NMR is shown. 1 - NMR data is shown in Table 4.
[0047] [ka]
[0048] [Table 1]
[0049] [Table 2]
[0050] [ka]
[0051] [Table 3]
[0052] [Table 4]
[0053] The canine heartworm disease control agent of the present invention contains a benzimidazole compound represented by general formula (1) or (1A) or a salt thereof as an active ingredient. The target animals of the canine heartworm disease control agent of the present invention are livestock such as cows, pigs, rabbits, and birds, or pets such as dogs, rabbits, and cats (hereinafter, the target animals, excluding humans), preferably dogs, but not limited thereto. In the present invention, control includes prevention and treatment.
[0054] Canine heartworm disease refers to nematodes of the order Spirurida, in particular (a) nematodes of the family Onchocercidae, e.g., Brugia spp., Brugia malayi, Brugia pahangi, Brugia patei; Dipetalonema spp., Dipetalonema reconditum; Dirofilaria spp., Dirofilaria immitis; Filaria spp., Filaria oculi; Onchocerca spp., Onchocerca cervicalis; (b) nematodes of the family Setariidae, e.g., Setaria spp., Setaria digitata, Setaria equina, Setaria labiatopapillosa, Setaria marshalli; (c) nematodes of the family Filariidae, e.g., Parafilaria spp., Parafilaria multipapillosa; Stephanofilaria spp.), Stephanofilaria assamensis, Stephanofilaria dedoesi, Stephanofilaria kaeli, Stephanofilaria okinawaensis, Stephanofilaria stilesi, etc., but are not limited to these.
[0055] When using the control agent of the present invention, the benzimidazole compound may be used as it is without adding any other components, but it is usually preferable to add excipients such as solid carriers and liquid carriers to the benzimidazole compound or its salts and formulate them into tablets, powders, granules, capsules, water-soluble agents, liquid agents, wettable powders, suspensions, etc. in accordance with conventional methods (such as the method described in "Pharmaceutical Science" edited by Otsuka Akinobu et al., 1995, Nankodo, etc.). Examples of excipients that are solid carriers include lactose, sucrose, glucose, corn starch, gelatin, casein, starch, gum arabic, cellulose derivatives, alginic acid, etc. Examples of excipients that are liquid carriers include water, glycerin, vegetable oils, fatty acids, fatty acid esters, sorbitol, etc.
[0056] The control agent of the present invention may further contain, for example, organic minerals such as peptide zinc and peptide iron, inorganic minerals such as zinc carbonate, manganese carbonate, iron sulfate, and magnesium carbonate, vitamins such as vitamin A, vitamin B, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, pantothenic acid, and nicotinic acid, alfalfa meal, rolled corn, and the like. In addition, flavors and the like may be fed at the same time to enhance palatability. If necessary, ordinary additives such as antibacterial agents, fungicides, anthelmintics, antioxidants, dyes, flavorings, flavorings, and enzymes may be mixed, and it is preferable to use the formulation in the form of powder, granules, liquid, tablet, etc. by ordinary methods. These formulations may contain a benzimidazole compound or its salt as an active ingredient, usually about 0.01 to 95% by weight.
[0057] The control agent of the present invention thus formulated can be used as is or after diluting with water, etc. In addition, other conventional additives such as antibacterial agents, antifungal agents, anthelmintics, antioxidants, colorants, flavorings, flavorings, and enzymes may be mixed or used simultaneously or non-simultaneously.
[0058] There is no particular limitation on the administration of the control agent of the present invention to the target animals, and it can be administered by a conventional method such as sprinkling or mixing with feed, as described below. The amount administered is an amount effective for controlling canine heartworm disease in the target animals, that is, an amount at which the control agent of the present invention is administered to enhance the control effect of canine heartworm disease in the target animals compared to when it is not administered, assuming that other conditions are the same.
[0059] The method of mixing and gelling the active ingredients of the control agent of the present invention to be administered to the target animals and allowing them to freely ingest the mixture can be carried out either at the hatchery or at the farm, and can also be carried out during the transportation of the target animals from the hatchery to the farm.
[0060] In addition, a gelling preparation can be prepared by mixing the active ingredient of the control agent of the present invention with a specified amount of water-soluble polysaccharide powder, and when used in hatcheries and farms, this can be diluted with water to form a gel-like solid, which can then be administered to the target animals (i.e., ad libitum intake or direct administration into the crop).
[0061] The formulated control agent is usually used alone, but can be used as a formulation dilution by diluting with water (i.e., administration by dilution with drinking water). The active ingredient concentration in the formulation dilution is usually preferably in the range of about 10 to 10,000 ppm, more preferably in the range of about 35 to 5,000 ppm. The method of administering the formulation dilution usually includes a method of dissolving about 0.01 to 500 g of the control agent in 1 L of water and processing it into the amount of administration liquid. Preferably, a method of dissolving about 0.035 to 350 g in 1 L of water and administering it can be mentioned.
[0062] To administer the thus prepared diluted formulation to the target animals, the diluted formulation may be administered using a drinking water addition device, etc. The amount of the diluted formulation to be administered may be appropriately determined depending on the size, growth condition, rearing density, administration method, etc. of the target animals, but is usually preferably about 300 to 2000 liters per 10,000 birds.
[0063] The timing and duration of administration of the control agent of the present invention is such that in egg-producing and meat-producing species, it is administered continuously throughout the entire life of the target animal, preferably during the young chick stage (chickens 0 to 5 weeks old after hatching) or 0 to 5 weeks after birth.
[0064] The dosage of the control agent may be appropriately determined depending on the type and size of the target animal, but generally, the total dosage is preferably in the range of 0.005 to 2 g, more preferably 0.005 to 1 g.
[0065] The control composition of the present invention is prepared by adding the control agent to animal feed, drinking water, physiological electrolyte solutions, etc. The amount of the control agent to be added is preferably within the range of about 0.005 to 10.0% by weight based on the total amount of the control composition.
[0066] The target animal feed, drinking water, or physiological electrolyte solution used in the control composition of the present invention is not particularly limited as long as it is one that is commonly used. Examples of these include feed prepared by appropriately mixing corn, rice, wheat, milo, soybean meal, bran, defatted rice bran, fish meal, skimmed milk powder, dried whey, oils and fats, alfalfa meal, North Sea meal, soybean oil and fat, powdered refined beef tallow, wheat flour, rapeseed oil and fat, meat and bone meal (feather meal), animal oils and fats, calcium phosphate, corn gluten meal, molasses, corn germ meal, calcium carbonate, tricalcium phosphate, sodium chloride, choline chloride, vitamins (vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin D, vitamin E, calcium pantothenate, nicotinamide, folic acid, etc.), amino acids (lysine, methionine, etc.), trace inorganic salts (magnesium sulfate, ferrous sulfate, copper sulfate, zinc sulfate, potassium iodide, cobalt sulfate, etc.), and live bacteria agents.
[0067] The control agent composition of the present invention may further contain, for example, organic minerals such as peptide zinc and peptide iron, inorganic minerals such as zinc carbonate, manganese carbonate, ferrous sulfate, and magnesium carbonate, vitamins such as vitamin A, vitamin B, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, pantothenic acid, and nicotinic acid, alfalfa meal, rolled corn, etc. In order to increase palatability, flavors and the like may be added at the same time.
[0068] There is no particular limitation on the method of administering the control composition of the present invention to the target animals, and it can be administered by any suitable method such as sprinkling or mixing with feed, as described below. The dose of the control composition is, in short, an amount effective for controlling heartworm disease in the target animals, that is, an amount at which the control effect of the control composition of the present invention is enhanced in the target animals when it is administered compared to when it is not administered, assuming that other conditions are the same.
[0069] The timing and duration of administration of the control agent composition of the present invention is such that in egg-producing and meat-producing species, the composition is administered continuously throughout the entire life of the target animal, preferably during the young chick stage (chickens 0-5 weeks old after hatching) or 0-5 weeks after birth, and more preferably for 0-21 days after hatching or for 0-21 days after birth.
[0070] When the control agent composition of the present invention is used by being mixed with feed for the target animal, the benzimidazole compound or its salt can be used at a ratio of about 0.0005 to 5% by weight, preferably about 0.05 to 2% by weight. When the control agent composition of the present invention is used by being added to drinking water or a physiological electrolyte solution, the benzimidazole compound or its salt can be used at a ratio of about 0.035 to 3.5% by weight, preferably about 0.035 to 1.4% by weight.
[0071] The control method of the present invention comprises a step of administering an effective amount of the control agent or the control composition of the present invention to a target animal. In the method, the control composition can be given to the animal in a conventional manner. The above-mentioned effective amount varies depending on the type of formulation, the target animal, the period of ingestion, and other conditions, and can be appropriately selected by increasing or decreasing the amount without being related to the above range.
[0072] Specifically, for example, the control agent of the present invention is diluted with water to a concentration suitable for administration to the target animal, and the resulting diluted solution is administered to the target animal. The dilution ratio may be applied in accordance with the conventional method of diluting and administering with drinking water, and for example, a dilution of about 5 to 10 times is preferably used. The control agent of the present invention is diluted with water to a predetermined concentration, and water-soluble polysaccharides are added and mixed with stirring to obtain a uniform solution, which is then left at room temperature or stored in a cool place (e.g., refrigerator, etc.) to obtain a gel-like solid. Alternatively, when using a gelling agent (e.g., agar, gelatin, etc.) that dissolves at high temperatures and solidifies at low temperatures, the gelling agent is added in advance to a medium for preparing the control agent of the present invention, the medium is sterilized with high-pressure steam, cooled, and left at room temperature or stored in a cool place (e.g., refrigerator, etc.) to obtain a gel-like solid. The gel-like solid obtained in this manner may be administered to the target animal. The gel strength of the gel when gelled is approximately 200 to 2000 g / cm 2 is appropriate, and when agar is used, this corresponds to a concentration of roughly 0.5 to 3.0%, although this differs depending on the type of agar.
[0073] Examples of polysaccharides used to gel the control agent of the present invention in an aqueous medium include agar, carrageenan, carboxymethylcellulose, starch, mannan, gelatin, sodium alginate, gum arabic, wax bean gum, xanthan gum, chitosan, guar gum, pectin, propyl glycol alginate, arabinogalactan, gum ghatti, tamarind seed gum, pullulan, morpholine fatty acid salts, curdlan, tragacanth gum, etc. Among these polysaccharides, it is particularly preferable to use agar, starch, mannan, and gelatin because they are inexpensive and easily available.
[0074] For example, when the gelled solid is administered to poultry, if it is administered to poultry of about 0 to 7 days old, which has a small amount of drinking water and feed intake, the necessary amount of the control agent of the present invention can be ingested in a short time in a labor-saving manner due to the genetic program (habit) of poultry to pick at solids on the floor with their beaks and ingest them. In this case, live bacteria agents, vaccines, drugs, nutrients, etc., which are difficult to administer to poultry at such a young age as described above, can also be efficiently administered to poultry at the same time as the control agent of the present invention by mixing them with the control agent of the present invention as necessary and gelling them with water-soluble polysaccharides. In addition, the supply of water and nutrients during the chick stage is extremely important for the subsequent productivity, and when nutrients are administered, carbohydrates such as monosaccharides such as glucose, mannose, fructose, and their oligosaccharides, disaccharides such as sucrose, proteins such as skim milk, lipids, vitamins, minerals, etc. can be mentioned.
[0075] In order to reinforce or complement the effect of the canine heartworm disease control agent of the present invention, an existing canine heartworm disease control agent can be used in combination. When using in combination, two or more active ingredients may be mixed before administration, or two or more different preparations may be administered separately. EXAMPLES
[0076] The present invention will be explained in more detail below with reference to Production Examples, Formulation Examples and Test Examples, but the present invention is not limited to these examples in any way.
[0077] Production Example 1. Production method of 5-(1-hexynyl)-2-furylaldehyde [ka] 5-Bromo-2-furylaldehyde (5.2g, 30mmol) and 1-hexyne (7.4g, 3.0 equivalents) were dissolved in THF (30mL) and triethylamine (18g, 6.0 equivalents) was added. After replacing the atmosphere in the reactor with argon, PdCl2(PPh3)2 (0.53g, 0.025 equivalents) and copper(I) iodide (0.29g, 0.050 equivalents) were added. After replacing the atmosphere in the reactor with argon again, the reaction was carried out at room temperature for 3 hours. The reaction solution was filtered through Celite, and the obtained filtrate was concentrated and purified by column chromatography to obtain the target product (4.7g, 89% yield).
[0078] Production Example 2. Method for producing 4,6-dibromo-2-(5-(1-hexynyl)-2-furyl)benzimidazole [ka] 5-(1-hexynyl)-2-furylaldehyde (88 mg, 0.5 mmol) was dissolved in ethanol (3 mL) and water (2 mL), and 2,4-dibromo-6-nitroaniline (0.15 g, 1.0 equivalent) and sodium dithionite (0.26 g, 3.0 equivalent) were added. The mixture was then heated to 70°C and reacted for 3 hours. After cooling to room temperature, an aqueous potassium carbonate solution was added for neutralization, and the mixture was extracted with ethyl acetate. After the solvent was distilled off, the product was purified by column chromatography to obtain the target product (93 mg, 44% yield).
[0079] Formulation example 1. Powder 25 parts of the benzimidazole compound and 25 parts of lactose are thoroughly mixed in a mortar, and the mixture is thoroughly stirred and mixed to obtain a powder.
[0080] Formulation example 2. Granules 25 parts of the benzimidazole compound and 25 parts of lactose are added and thoroughly mixed. Then, an appropriate amount of water is added to the mixture, which is further stirred, granulated in a granulator, and dried under air to obtain granules.
[0081] Formulation example 3. Wettable powder 25 parts of a benzimidazole compound, 65 parts of diatomaceous earth, 5 parts of a higher alcohol sulfate, and 5% of an alkylnaphthalene sulfonate are uniformly mixed and finely pulverized to obtain a wettable powder.
[0082] Test Example 1. Evaluation test of the effect on the movement of dog heartworm (Dirofilaria immitis) larvae 500 L-1 stage larvae of dog heartworms diluted in a prescribed preparation solution were inoculated into each well of a 96-well plate, and a DMSO diluted solution of the benzimidazole compound or its salt represented by the general formula (1) of the present invention was added to the well to a final concentration of 50 ppm. After that, the well was left to stand for 3 days, and its motility was investigated. The motility inhibition rate of each treatment group was corrected and calculated based on the inhibitory power of the DMSO solution alone, and judged according to the following criteria.
[0083] Judgment criteria A: Corrected movement inhibition rate 100% B: Correction movement inhibition rate 99%~90% C... Corrected movement inhibition rate 89%~80% D: Corrected movement inhibition rate: 79% to 50%
[0084] As a result, the compound 2-1 of the present invention exhibited activity A.
[0085] Test Example 2. Evaluation test of the effect on the growth of dog heartworm (Dirofilaria immitis) A specific preparation solution, 8 to 20 L-3 stage larvae of dog heartworm, and a DMSO diluted solution of the benzimidazole compound of the present invention were added to each well of a 24-well plate to make the final concentration 50 ppm. After 7 days, the number of larvae that had developed to the L-4 stage was counted, and the growth inhibition rate from L3 stage larvae to L4 stage larvae was calculated.
[0086] As a result, among the compounds represented by the general formula (1) of the present invention, the compounds Nos. 1-7, 1-11, 1-16, 1-18, and 1-36 exhibited a growth inhibition rate of 50% or more. [Industrial Applicability]
[0087] The present invention can provide an agent for controlling heartworm disease in animals that is highly effective when administered to a target animal, and a method for using the agent for controlling heartworm disease in a target animal using the same.
Claims
1. General formula (1) 【Chemistry 1】 {During the ceremony, R is (a1) a hydrogen atom; (a2) (C 1 -C 6 ) alkyl group; (a3) Halo (C 1 -C 6 ) alkyl group; (a4) (C 2 -C 6 ) alkenyl group; (a5) (C 2 -C 6 ) an alkynyl group; (a6) (C 1 -C 6 ) Alkoxy (C 1 -C 6 ) alkyl group; (a7) (C 1 -C 6 ) alkylthio (C 1 -C 6 ) alkyl group; (a8) (C 1 -C 6 ) alkoxycarbonyl (C 1 -C 6 ) alkyl group; (a9) (C 1 -C 6 ) an alkoxycarbonyl group; (a10) an aryl group; (a11) may be the same or different, (a) a halogen atom, (b) (C 1 -C 6 ) alkyl group, (c) halo (C 1 -C 6 ) alkyl group, (d) (C 1 -C 6 ) alkoxy group, (e) halo (C 1 -C 6 ) an alkoxy group, (f) (C 1 -C 6 ) alkylthio group, (g) halo (C 1 -C 6 ) an alkylthio group, (h) (C 1 -C 6 ) alkylsulfinyl group, (i) halo (C 1 -C 6 (l) an aryl group having 1 to 5 substituents selected from an alkylsulfinyl group, a nitro group, and (m) a trimethylsilyl group; (a12) Aryl (C 1 -C 6 ) alkyl group; (a13) may be the same or different, (a) a halogen atom, (b) (C 1 -C 6 ) alkyl group, (c) halo (C 1 -C 6 ) alkyl group, (d) (C 1 -C 6 ) alkoxy group, (e) halo (C 1 -C 6 ) an alkoxy group, (f) (C 1 -C 6 ) alkylthio group, (g) halo (C 1 -C 6 ) an alkylthio group, (h) (C 1 -C 6 ) alkylsulfinyl group, (i) halo (C 1 -C 6 ) an alkylsulfinyl group, (j) (C 1 -C 6 ) alkylsulfonyl group, (k) halo (C 1 -C 6 ) an aryl group having 1 to 5 substituents selected from an alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group (C 1 -C 6 ) alkyl group; (a14) Aryl (C 2 -C 6 ) alkenyl group; (a15) may be the same or different, (a) a halogen atom, (b) (C 1 -C 6 ) alkyl group, (c) halo (C 1 -C 6 ) alkyl group, (d) (C 1 -C 6 ) alkoxy group, (e) halo (C 1 -C 6 ) an alkoxy group, (f) (C 1 -C 6 ) alkylthio group, (g) halo (C 1 -C 6 ) an alkylthio group, (h) (C 1 -C 6 ) alkylsulfinyl group, (i) halo (C 1 -C 6 ) an alkylsulfinyl group, (j) (C 1 -C 6 ) alkylsulfonyl group, (k) halo (C 1 -C 6 ) an aryl group having 1 to 5 substituents selected from an alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group (C 2 -C 6 ) alkenyl group; (a16) Aryl (C 1 -C 6 ) Alkoxy (C 1 -C 6 ) alkyl group; (a17) may be the same or different, (a) a halogen atom, (b) (C 1 -C 6 ) alkyl group, (c) halo (C 1 -C 6 ) alkyl group, (d) (C 1 -C 6 ) alkoxy group, (e) halo (C 1 -C 6 ) an alkoxy group, (f) (C 1 -C 6 ) alkylthio group, (g) halo (C 1 -C 6 ) an alkylthio group, (h) (C 1 -C 6 ) alkylsulfinyl group, (i) halo (C 1 -C 6 ) an alkylsulfinyl group, (j) (C 1 -C 6 ) alkylsulfonyl group, (k) halo (C 1 -C 6 ) an aryl group having 1 to 5 substituents selected from an alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group (C 1 -C 6 ) Alkoxy (C 1 -C 6 ) alkyl group; (a18) R 3 R 4 N group (where R 3 and R 4 may be the same or different, (aa) a hydrogen atom, (ab) (C 1 -C 6 ) alkyl group, (ac) (C 1 -C 6 ) an alkoxy group, (ad) (C 1 -C 6 ) an alkoxycarbonyl group, (ae) (C 1 -C 6 ) alkylsulfonyl group, (af) halo (C 1 -C 6 ) an alkylsulfonyl group, or (ag) a phenyl group; (a19) R 3 R 4 N carbonyl group (where R 3 and R 4 is the same as above.) (a20) R 3 R 4 N-thiocarbonyl group (where R 3 and R 4 is the same as above; or (a21) R 3 R 4 N sulfonyl group (where R 3 and R 4 is the same as above. ) ; indicates. Y 1 and Y 4 may be the same or different, (d1) a hydrogen atom; (d2) a halogen atom; or (d3) (C 1 -C 6 ) alkyl group; Y 2 and Y 3 may be the same or different, (e1) a hydrogen atom; (e2) a halogen atom; (e3) (C 1 -C 6 ) alkyl group; (e4) (C 1 -C 6 ) an alkoxy group; (e5) Halo (C 1 -C 6 ) alkyl group; (e6) Halo (C 1 -C 6 ) an alkoxy group; (e7) an aryloxy group; (e8) may be the same or different, (a) a halogen atom, (b) (C 1 -C 6 ) alkyl group, (c) halo (C 1 -C 6 ) alkyl group, (d) (C 1 -C 6 ) alkoxy group, (e) halo (C 1 -C 6 ) an alkoxy group, (f) (C 1 -C 6 ) alkylthio group, (g) halo (C 1 -C 6 ) an alkylthio group, (h) (C 1 -C 6 ) alkylsulfinyl group, (i) halo (C 1 -C 6 ) an alkylsulfinyl group, (j) (C 1 -C 6 ) alkylsulfonyl group, (k) halo (C 1 -C 6 (l) an aryloxy group having 1 to 5 substituents selected from an alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group; (e9) an arylcarbonyl group; or (e10) may be the same or different, (a) a halogen atom, (b) (C 1 -C 6 ) alkyl group, (c) halo (C 1 -C 6 ) alkyl group, (d) (C 1 -C 6 ) alkoxy group, (e) halo (C 1 -C 6 ) an alkoxy group, (f) (C 1 -C 6 ) alkylthio group, (g) halo (C 1 -C 6 ) an alkylthio group, (h) (C 1 -C 6 ) alkylsulfinyl group, (i) halo (C 1 -C 6 ) an alkylsulfinyl group, (j) (C 1 -C 6 ) alkylsulfonyl group, (k) halo (C 1 -C 6 (l) an aryloxy group having 1 to 5 substituents selected from an alkylsulfonyl group, a nitro group, and (m) a trimethylsilyl group; X may be the same or different, (c1) a hydrogen atom; (c2) a halogen atom; (b1) (C 6 -C 12 ) alkyl group; (b2) (C 6 -C 12 ) an alkenyl group; or (b3) (C 6 -C 12 ) an alkynyl group; n represents an integer of 3.
1. An animal control agent for heartworm disease, comprising as an active ingredient a benzimidazole compound represented by the following formula:
2. A compound represented by the general formula (1) for producing an agent for controlling canine heartworm disease in animals. 【Chemistry 2】 {During the ceremony, R is (a1) a hydrogen atom; (a2) (C1-C6) alkyl groups; (a3) halo(C 1 -C 6 )alkyl groups; (a4) (C2-C6) alkenyl group; (a5) (C2-C6) alkynyl group; (a6) (C1-C6)alkoxy(C1-C6)alkyl groups; (a7) (C 1 -C 6 ) alkylthio(C 1 -C 6 ) alkyl groups; (a8) (C 1 -C 6 )alkoxycarbonyl(C 1 -C 6 )alkyl groups; (a9) (C 1 -C 6 )alkoxycarbonyl group; (a10) an aryl group; (a11) an aryl group having 1 to 5 substituents which may be the same or different and are selected from (a) a halogen atom, (b) a (C1-C6) alkyl group, (c) a halo(C1-C6) alkyl group, (d) a (C1-C6) alkoxy group, (e) a halo(C1-C6) alkoxy group, (f) a (C1-C6) alkylthio group, (g) a halo(C1-C6) alkylthio group, (h) a (C1-C6) alkylsulfinyl group, (i) a halo(C1-C6) alkylsulfinyl group, (l) a nitro group, and (m) a trimethylsilyl group; (a12) aryl(C1-C6)alkyl groups; (a13) aryl(C 1 -C 6 )alkyl groups having 1 to 5 substituents which may be the same or different and are selected from (a) a halogen atom, (b) a (C 1 -C 6 )alkyl group, (c) a halo(C 1 -C 6 )alkyl group, (d) a (C 1 -C 6 )alkoxy group, (e) a halo(C 1 -C 6 )alkoxy group, (f) a (C 1 -C 6 )alkylthio group, (g) a halo(C 1 -C 6 )alkylthio group, (h) a (C 1 -C 6 )alkylsulfinyl group, (i) a halo(C 1 -C 6 )alkylsulfinyl group, (j) a (C 1 -C 6 )alkylsulfonyl group, (k) a halo(C 1 -C 6 )alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group; (a14) aryl(C2-C6)alkenyl group; (a15) aryl(C2-C6) having 1 to 5 substituents which may be the same or different and are selected from (a) a halogen atom, (b) a (C1-C6) alkyl group, (c) a halo(C1-C6) alkyl group, (d) a (C1-C6) alkoxy group, (e) a halo(C1-C6) alkoxy group, (f) a (C1-C6) alkylthio group, (g) a halo(C1-C6) alkylthio group, (h) a (C1-C6) alkylsulfinyl group, (i) a halo(C1-C6) alkylsulfinyl group, (j) a (C1-C6) alkylsulfonyl group, (k) a halo(C1-C6) alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group. ) alkenyl group; (a16) aryl(C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl groups; (a17) aryl(C 1 -C 6 )alkoxy(C 1 -C 6 ) groups which may be the same or different and have 1 to 5 substituents selected from (a) a halogen atom, (b) a (C 1 -C 6 )alkyl group, (c) a halo(C 1 -C 6 )alkyl group, (d) a (C 1 -C 6 )alkoxy group, (e) a halo(C 1 -C 6 )alkoxy group, (f) a (C 1 -C 6 )alkylthio group, (g) a halo(C 1 -C 6 )alkylthio group, (h) a (C 1 -C 6 )alkylsulfinyl group, (i) a halo(C 1 -C 6 )alkylsulfinyl group, (j) a (C 1 -C 6 )alkylsulfonyl group, (k) a halo(C 1 -C 6 )alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group; 1-C6) alkyl groups; (a18) an R3R4N group, where R3 and R4 may be the same or different and represent (aa) a hydrogen atom, (ab) a (C1-C6) alkyl group, (ac) a (C1-C6) alkoxy group, (ad) a (C1-C6) alkoxycarbonyl group, (ae) a (C1-C6) alkylsulfonyl group, (af) a halo(C1-C6) alkylsulfonyl group, or (ag) a phenyl group; (a19) R 3 R 4 N carbonyl group (wherein R 3 and R 4 are as defined above); (a20) R 3 R 4 N thiocarbonyl group (wherein R 3 and R 4 are the same as above); or (a21) R 3 R 4 N represents a sulfonyl group (wherein R 3 and R 4 are as defined above). Y 1 and Y 4 may be the same or different; (d1) a hydrogen atom; (d2) a halogen atom; or (d3) a (C 1 -C 6 ) alkyl group; Y 2 and Y 3 may be the same or different; (e1) a hydrogen atom; (e2) a halogen atom; (e3) (C1-C6) alkyl groups; (e4) (C 1 -C 6 )alkoxy group; (e5) halo(C 1 -C 6 )alkyl groups; (e6) a halo(C 1 -C 6 )alkoxy group; (e7) an aryloxy group; (e8) an aryloxy group having 1 to 5 substituents which may be the same or different and are selected from (a) a halogen atom, (b) a (C1-C6) alkyl group, (c) a halo(C1-C6) alkyl group, (d) a (C1-C6) alkoxy group, (e) a halo(C1-C6) alkoxy group, (f) a (C1-C6) alkylthio group, (g) a halo(C1-C6) alkylthio group, (h) a (C1-C6) alkylsulfinyl group, (i) a halo(C1-C6) alkylsulfinyl group, (j) a (C1-C6) alkylsulfonyl group, (k) a halo(C1-C6) alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group; (e9) an arylcarbonyl group; or (e10) an aryloxy group having 1 to 5 substituents which may be the same or different and are selected from (a) a halogen atom, (b) a (C1-C6) alkyl group, (c) a halo(C1-C6) alkyl group, (d) a (C1-C6) alkoxy group, (e) a halo(C1-C6) alkoxy group, (f) a (C1-C6) alkylthio group, (g) a halo(C1-C6) alkylthio group, (h) a (C1-C6) alkylsulfinyl group, (i) a halo(C1-C6) alkylsulfinyl group, (j) a (C1-C6) alkylsulfonyl group, (k) a halo(C1-C6) alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group. X may be the same or different, (c1) a hydrogen atom; (c2) a halogen atom; (b1) (C6-C12) alkyl groups; (b2) a (C6-C12) alkenyl group; or (b3) a (C 6 -C 12 ) alkynyl group; n represents an integer of 3. Use of a benzimidazole compound represented by the following formula (1) or a salt thereof.
3. General formula (1A) 【Chemistry 3】 {During the ceremony, R is (a1) a hydrogen atom; (a2) (C 1 -C 6 ) alkyl group; (a3) Halo (C 1 -C 6 ) alkyl group; (a4) (C 2 -C 6 ) alkenyl group; (a5) (C 2 -C 6 ) an alkynyl group; (a6) (C 1 -C 6 ) Alkoxy (C 1 -C 6 ) alkyl group; (a7) (C 1 -C 6 ) alkylthio (C 1 -C 6 ) alkyl group; (a8) (C 1 -C 6 ) alkoxycarbonyl (C 1 -C 6 ) alkyl group; (a9) (C 1 -C 6 ) an alkoxycarbonyl group; (a10) an aryl group; (a11) may be the same or different, (a) a halogen atom, (b) (C 1 -C 6 ) alkyl group, (c) halo (C 1 -C 6 ) alkyl group, (d) (C 1 -C 6 ) alkoxy group, (e) halo (C 1 -C 6 ) an alkoxy group, (f) (C 1 -C 6 ) alkylthio group, (g) halo (C 1 -C 6 ) an alkylthio group, (h) (C 1 -C 6 ) alkylsulfinyl group, (i) halo (C 1 -C 6 (l) an aryl group having 1 to 5 substituents selected from an alkylsulfinyl group, a nitro group, and (m) a trimethylsilyl group; (a12) Aryl (C 1 -C 6 ) alkyl group; (a13) may be the same or different, (a) a halogen atom, (b) (C 1 -C 6 ) alkyl group, (c) halo (C 1 -C 6 ) alkyl group, (d) (C 1 -C 6 ) alkoxy group, (e) halo (C 1 -C 6 ) an alkoxy group, (f) (C 1 -C 6 ) alkylthio group, (g) halo (C 1 -C 6 ) an alkylthio group, (h) (C 1 -C 6 ) alkylsulfinyl group, (i) halo (C 1 -C 6 ) an alkylsulfinyl group, (j) (C 1 -C 6 ) alkylsulfonyl group, (k) halo (C 1 -C 6 ) an aryl group having 1 to 5 substituents selected from an alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group (C 1 -C 6 ) alkyl group; (a14) Aryl (C 2 -C 6 ) alkenyl group; (a15) may be the same or different, (a) a halogen atom, (b) (C 1 -C 6 ) alkyl group, (c) halo (C 1 -C 6 ) alkyl group, (d) (C 1 -C 6 ) alkoxy group, (e) halo (C 1 -C 6 ) an alkoxy group, (f) (C 1 -C 6 ) alkylthio group, (g) halo (C 1 -C 6 ) an alkylthio group, (h) (C 1 -C 6 ) alkylsulfinyl group, (i) halo (C 1 -C 6 ) an alkylsulfinyl group, (j) (C 1 -C 6 ) alkylsulfonyl group, (k) halo (C 1 -C 6 ) an aryl group having 1 to 5 substituents selected from an alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group (C 2 -C 6 ) alkenyl group; (a16) Aryl (C 1 -C 6 ) Alkoxy (C 1 -C 6 ) alkyl group; (a17) may be the same or different, (a) a halogen atom, (b) (C 1 -C 6 ) alkyl group, (c) halo (C 1 -C 6 ) alkyl group, (d) (C 1 -C 6 ) alkoxy group, (e) halo (C 1 -C 6 ) an alkoxy group, (f) (C 1 -C 6 ) alkylthio group, (g) halo (C 1 -C 6 ) an alkylthio group, (h) (C 1 -C 6 ) alkylsulfinyl group, (i) halo (C 1 -C 6 ) an alkylsulfinyl group, (j) (C 1 -C 6 ) alkylsulfonyl group, (k) halo (C 1 -C 6 ) an aryl group having 1 to 5 substituents selected from an alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group (C 1 -C 6 ) Alkoxy (C 1 -C 6 ) alkyl group; (a18) R 3 R 4 N group (where R 3 and R 4 may be the same or different, (aa) a hydrogen atom, (ab) (C 1 -C 6 ) alkyl group, (ac) (C 1 -C 6 ) an alkoxy group, (ad) (C 1 -C 6 ) an alkoxycarbonyl group, (ae) (C 1 -C 6 ) alkylsulfonyl group, (af) halo (C 1 -C 6 ) an alkylsulfonyl group, or (ag) a phenyl group; (a19) R 3 R 4 N carbonyl group (where R 3 and R 4 is the same as above.) (a20) R 3 R 4 N-thiocarbonyl group (where R 3 and R 4 is the same as above; or (a21) R 3 R 4 N sulfonyl group (where R 3 and R 4 is the same as above. ) ; indicates. X 1 teeth, (b1) (C 6 -C 12 ) alkyl group; (b2) (C 6 -C 12 ) an alkenyl group; or (b3) (C 6 -C 12 ) an alkynyl group; X 2 and X 3 may be the same or different, (c1) a hydrogen atom; (c2) a halogen atom; or (c3) (C 1 -C 6 ) alkyl group; Y 1 and Y 4 may be the same or different, (d1) a hydrogen atom; (d2) a halogen atom; or (d3) (C 1 -C 6 ) alkyl group; Y 2 and Y 3 may be the same or different, (e1) a hydrogen atom; (e2) a halogen atom; (e3) (C 1 -C 6 ) alkyl group; (e4) (C 1 -C 6 ) an alkoxy group; (e5) Halo (C 1 -C 6 ) alkyl group; (e6) Halo (C 1 -C 6 ) an alkoxy group; (e7) an aryloxy group; (e8) may be the same or different, (a) a halogen atom, (b) (C 1 -C 6 ) alkyl group, (c) halo (C 1 -C 6 ) alkyl group, (d) (C 1 -C 6 ) alkoxy group, (e) halo (C 1 -C 6 ) an alkoxy group, (f) (C 1 -C 6 ) alkylthio group, (g) halo (C 1 -C 6 ) an alkylthio group, (h) (C 1 -C 6 ) alkylsulfinyl group, (i) halo (C 1 -C 6 ) an alkylsulfinyl group, (j) (C 1 -C 6 ) alkylsulfonyl group, (k) halo (C 1 -C 6 (l) an aryloxy group having 1 to 5 substituents selected from an alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group; (e9) an arylcarbonyl group; or (e10) may be the same or different, (a) a halogen atom, (b) (C 1 -C 6 ) alkyl group, (c) halo (C 1 -C 6 ) alkyl group, (d) (C 1 -C 6 ) alkoxy group, (e) halo (C 1 -C 6 ) an alkoxy group, (f) (C 1 -C 6 ) alkylthio group, (g) halo (C 1 -C 6 ) an alkylthio group, (h) (C 1 -C 6 ) alkylsulfinyl group, (i) halo (C 1 -C 6 ) an alkylsulfinyl group, (j) (C 1 -C 6 ) alkylsulfonyl group, (k) halo (C 1 -C 6 (l) an aryloxy group having 1 to 5 substituents selected from an alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group. The benzimidazole compound represented by the formula (I) or a salt thereof.
4. R is, (a1) a hydrogen atom; (a2) (C 1 -C 6 ) alkyl group; (a3) Halo (C 1 -C 6 ) alkyl group; (a4) (C 2 -C 6 ) alkenyl group; (a5) (C 2 -C 6 ) an alkynyl group; (a6) (C 1 -C 6 ) Alkoxy (C 1 -C 6 ) alkyl group; (a7) (C 1 -C 6 ) alkylthio (C 1 -C 6 ) alkyl group; (a8) (C 1 -C 6 ) alkoxycarbonyl (C 1 -C 6 ) alkyl group; (a9) (C 1 -C 6 ) an alkoxycarbonyl group; (a11) may be the same or different, (a) a halogen atom, (b) (C 1 -C 6 ) alkyl group, (c) halo (C 1 -C 6 ) alkyl group, (d) (C 1 -C 6 ) alkoxy group, (e) halo (C 1 -C 6 ) an alkoxy group, (f) (C 1 -C 6 ) alkylthio group, (g) halo (C 1 -C 6 ) an alkylthio group, (h) (C 1 -C 6 ) alkylsulfinyl group, (i) halo (C 1 -C 6 (l) an aryl group having 1 to 5 substituents selected from an alkylsulfinyl group, a nitro group, and (m) a trimethylsilyl group; (a12) Aryl (C 1 -C 6 ) alkyl group; (a13) may be the same or different, (a) a halogen atom, (b) (C 1 -C 6 ) alkyl group, (c) halo (C 1 -C 6 ) alkyl group, (d) (C 1 -C 6 ) alkoxy group, (e) halo (C 1 -C 6 ) an alkoxy group, (f) (C 1 -C 6 ) alkylthio group, (g) halo (C 1 -C 6 ) an alkylthio group, (h) (C 1 -C 6 ) alkylsulfinyl group, (i) halo (C 1 -C 6 ) an alkylsulfinyl group, (j) (C 1 -C 6 ) alkylsulfonyl group, (k) halo (C 1 -C 6 ) an aryl group having 1 to 5 substituents selected from an alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group (C 1 -C 6 ) alkyl group; (a14) Aryl (C 2 -C 6 ) alkenyl group; (a16) Aryl (C 1 -C 6 ) Alkoxy (C 1 -C 6 ) alkyl group; (a20) R 3 R 4 N-thiocarbonyl group (where R 3 and R 4 is the same as above; or (a21) R 3 R 4 N sulfonyl group (where R 3 and R 4 is the same as above.) X 1 but, (b1) (C 6 -C 12 ) alkyl group; or (b3) (C 6 -C 12 ) an alkynyl group; X 2 and X 3 may be the same or different, (c1) a hydrogen atom; or (c2) a halogen atom; Y 1 and Y 4 may be the same or different, (d1) a hydrogen atom; (d2) a halogen atom; or (d3) (C 1 -C 6 ) alkyl group; Y 2 and Y 3 may be the same or different, (e1) a hydrogen atom; (e2) a halogen atom; (e3) (C 1 -C 6 ) alkyl group; (e4) (C 1 -C 6 ) an alkoxy group; (e5) Halo (C 1 -C 6 ) alkyl group; (e6) Halo (C 1 -C 6 ) an alkoxy group; (e7) an aryloxy group; or (e9) an arylcarbonyl group; The benzimidazole compound or a salt thereof according to claim 3.
5. 5. A method for controlling heartworm disease in animals, comprising the step of administering to said animal a benzimidazole compound or a salt thereof according to claim 3 or 4 as an active ingredient.
6. Use of the benzimidazole compound or a salt thereof according to any one of claims 3 to 4 for the manufacture of an agent for controlling heartworm disease in animals.
Citation Information
Patent Citations
Treating animals for helminthiasis
GB1140397A
Benzimidazole compound or salt thereof, agricultural and horticultural insecticidal and acaricidal agent containing said compound, and method for using same
WO2019225663A1
Benzimidazole compound or salts thereof, agricultural and horticultural insecticide / acaricide containing said compound, and method for using same
WO2021107113A1
